NEW YORK, July 30 – Exelixis of South San Francisco, Calif., has filed a shelf registration with the Securities and Exchange Commission to offer up to $150 million in common stock.

The company said it was considering raising additional funds to help support the development of cancer drug rebeccamycin, which it recently acquired from Bristol-Myers Squibb, as well as for other drug discovery and corporate activities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.